A phase III clinical trial has shown that an ultra-hypofractionated radiotherapy regimen delivered over 2.5 weeks is as safe and effective as the conventional 8-week course for treating localized prostate cancer, maintaining comparable outcomes over 10 years. Presented at ESTRO 2025, the study confirmed that the shorter course does not increase long-term side effects and provides equally durable cancer control. This translates to a more efficient treatment protocol with significant benefits for patients and health systems.

Source: ESTRO 2025